Trial Profile
A phase II study of Amikacin/fosfomycin in non-CF bronchiectasis patients with chronic lung infection and frequent exacerbations
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2018
Price :
$35
*
At a glance
- Drugs Amikacin/fosfomycin (Primary) ; Molgramostim (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- 29 Nov 2018 New trial record
- 07 Nov 2018 According to a Savara Pharmaceuticals media release, the company expects to announce the initial indication for the study early in 2019, with an anticipated study-start later in 2019.